X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB GLENMARK PHARMA DR. REDDYS LAB/
GLENMARK PHARMA
 
P/E (TTM) x 29.0 20.0 145.1% View Chart
P/BV x 3.6 3.5 102.2% View Chart
Dividend Yield % 0.7 0.3 245.4%  

Financials

 DR. REDDYS LAB   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
GLENMARK PHARMA
Mar-18
DR. REDDYS LAB/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788930 299.8%   
Low Rs1,902517 367.5%   
Sales per share (Unadj.) Rs860.8322.6 266.8%  
Earnings per share (Unadj.) Rs57.128.5 200.3%  
Cash flow per share (Unadj.) Rs122.039.2 311.3%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.90.3 308.6%  
Book value per share (Unadj.) Rs757.7183.0 414.1%  
Shares outstanding (eoy) m165.91282.17 58.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.72.2 121.4%   
Avg P/E ratio x41.125.4 161.8%  
P/CF ratio (eoy) x19.218.5 104.1%  
Price / Book Value ratio x3.14.0 78.2%  
Dividend payout %35.07.0 499.2%   
Avg Mkt Cap Rs m389,034204,206 190.5%   
No. of employees `00023.513.7 171.5%   
Total wages/salary Rs m32,14918,718 171.8%   
Avg. sales/employee Rs Th6,070.86,636.8 91.5%   
Avg. wages/employee Rs Th1,366.61,364.7 100.1%   
Avg. net profit/employee Rs Th402.5586.1 68.7%   
INCOME DATA
Net Sales Rs m142,81091,031 156.9%  
Other income Rs m1,552914 169.8%   
Total revenues Rs m144,36291,945 157.0%   
Gross profit Rs m23,51216,154 145.6%  
Depreciation Rs m10,7723,019 356.8%   
Interest Rs m7882,856 27.6%   
Profit before tax Rs m13,50411,193 120.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3803,155 138.8%   
Profit after tax Rs m9,4688,039 117.8%  
Gross profit margin %16.517.7 92.8%  
Effective tax rate %32.428.2 115.1%   
Net profit margin %6.68.8 75.1%  
BALANCE SHEET DATA
Current assets Rs m104,98469,887 150.2%   
Current liabilities Rs m68,93832,879 209.7%   
Net working cap to sales %25.240.7 62.1%  
Current ratio x1.52.1 71.6%  
Inventory Days Days7481 91.3%  
Debtors Days Days10493 110.8%  
Net fixed assets Rs m104,38528,892 361.3%   
Share capital Rs m830282 294.1%   
"Free" reserves Rs m124,88651,353 243.2%   
Net worth Rs m125,71651,635 243.5%   
Long term debt Rs m25,08941,418 60.6%   
Total assets Rs m225,443125,954 179.0%  
Interest coverage x18.14.9 368.7%   
Debt to equity ratio x0.20.8 24.9%  
Sales to assets ratio x0.60.7 87.6%   
Return on assets %4.58.6 52.6%  
Return on equity %7.515.6 48.4%  
Return on capital %9.715.1 64.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,62336,317 200.0%   
Fx outflow Rs m18,9169,720 194.6%   
Net fx Rs m53,70726,598 201.9%   
CASH FLOW
From Operations Rs m18,03016,481 109.4%  
From Investments Rs m-14,883-10,133 146.9%  
From Financial Activity Rs m-4,440-4,685 94.8%  
Net Cashflow Rs m-1,2361,770 -69.8%  

Share Holding

Indian Promoters % 25.5 48.3 52.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 6.9 78.3%  
FIIs % 35.3 34.4 102.6%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 10.5 145.7%  
Shareholders   75,885 56,727 133.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Dec 11, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS